Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$23.9M
2M shares
52-week range
$2.88 – $18.20
64% from low
Exchange
NASDAQ
CS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.0K | $6.0K | $5.0K | $4.0K | $118.0K | $342.0K |
| Gross profit | −$1.0K | −$6.0K | −$5.0K | −$4.0K | −$118.0K | −$342.0K |
| Gross margin | — | — | — | — | — | — |
| R&D | $38.0K | $245.0K | $347.0K | $332.0K | $534.0K | $2.1M |
| Operating income | −$72.0K | −$703.0K | −$895.0K | −$635.0K | −$1.3M | −$6.2M |
| EBITDA | −$72.0K | −$703.0K | −$772.0K | −$631.0K | −$1.4M | −$5.9M |
| Net income | −$73.0K | −$711.0K | −$779.0K | −$600.0K | −$1.5M | −$3.3M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | 0.00 | -134.14 | -2.07 |
Annual figures · source: Financial Modeling Prep
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.
www.polyrizon-biotech.comNo one on the platform currently holds PLRZ.
No tracked institution reports a position in PLRZ as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-11-28 | 1-for-6reverse |
| 2025-05-27 | 1-for-250reverse |
No one on the platform has traded PLRZ yet.
| $39M |
| — |
| PMCBPharmaCyte Biotech, Inc. | $0.73 | -5.03% | $5M | — |
| QNRXQuoin Pharmaceuticals, Ltd. | $4.55 | +2.25% | $9M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$PLRZ Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
View on StockTwits ↗Premarket top gainers (2/2) $FCEL +16.8% ($25.49) $BNC +14.5% ($2.60) $ENRD +12.6% ($6.90) $INMD +12.0% ($14.95) $PLRZ +10.1% ($12.99)
View on StockTwits ↗$ADTX last year plenty of times $PLRZ $0.003 no pre r/s bounce but doubled in that week $HCTI barcoded $0.007-$0.02 for 2 months then ran 10x $GNLN went to $0.007, had no run pre-r/s but did after And on and on… ADTX for me feels most like HCTI
View on StockTwits ↗$ADTX $PLRZ went to about $0.003 last year before their r/s
View on StockTwits ↗$PLRZ well positioned with patents allowing to streamline marketing and distribution upon approval from fda following human trials set to begin any day now
View on StockTwits ↗$PLRZ 08:17 on Jun. 17 2026 Polyrizon Publishes U.S. Patent Application No. US 2024/0358741 A1, titled "Mucoadhesive Polymers for Nasal Drug Delivery" #tradeideas
View on StockTwits ↗$PLRZ started a human study to characterize nasal residence time of its NASARIX allergy blocker.
View on StockTwits ↗$PLRZ 08:10 on Jun. 15 2026 Polyrizon Launches Human Study With Top European Medical Center To Validate NASARIX Allergy Blocker's Nasal Residence Time #tradeideas
View on StockTwits ↗$PLRZ volume 17,000 . Just stop giving this company attention . Let them figure it out 
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.